June 27, 2022 10:35 AM EDT

Mitochondria biotech receives Morningside buyout offer after PhII fail; Oncology microcap withdraws IPO plans

Paul Schloesser

Associate Editor

Not even two months after reporting a Phase II fail for its lead drug candidate, Stealth BioTherapeutics is now being eyed for a potential acquisition …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mitochondria biotech receives Morningside buyout offer after PhII fail; Oncology microcap withdraws IPO plans

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mi­to­chon­dria biotech re­ceives Morn­ing­side buy­out of­fer af­ter PhII fail; On­col­o­gy mi­cro­cap with­draws IPO plans

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Mitochondria biotech receives Morningside buyout offer after PhII fail; Oncology microcap withdraws IPO plans